Recent BioUtah News & Events

Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnostics.

INTEGUMENT-INFANT showed 49.1% achieving vIGA-AD clear/almost clear at week 4 and 27.3% meeting vIGA-AD Success, alongside rapid pruritus improvement.

resentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases.

Physician and U.S. Rep. Mike Kennedy (R-UT) toured the Edwards Lifesciences plant in Draper, UT, on Wednesday.

Collaboration connects European development expertise with U.S. manufacturing to give medtech innovators a seamless path from concept to commercialization for safety-critical medical devices.

Newman presents evidence that direct contracting can lower healthcare costs, improve transparency, and return savings to workers.

More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs.

Project designed to support supply chain continuity for customers relying on the company for their cell culture needs.

The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.

Alzheimer’s disease is one of the world’s most pressing health challenges, affecting more than 55 million people globally; a number expected to nearly triple by 2050.

Collaboration strengthens Ratio’s long-term isotope supply strategy for clinical development and future pipeline growth.

SkinTE® would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved.

Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and – for the first time – measurable reduction in individual patient risk trajectories over 24 months

Indication expansion addresses a major pediatric gap where topical corticosteroids are commonly used off-label yet constrained by sensitive-site and long-term continuous-use limitations.

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis.

ASE 2026 data support further development of MVT-100 in pivotal trials.

The automated PCR test provides results in 20 minutes to help clinicians diagnose common causes of vaginitis during a patient visit.

FIRST OF THREE STEPS TOWARD BRINGING NOVEL RADIOISOTOPE PRODUCTION PLATFORM ONLINE

Novel gel embolic designed to give physicians greater control and consistency during embolization.

BioUtah, alongside state and local partners, showcased Utah’s booming $22.6B+ life sciences sector at the BIO International Convention, June 22-25, at the San Diego Convention Center. Through the Utah Pavilion Exhibit, the delegation boosted the state’s global profile as a premier bioscience hub. A number of meetings with entrepreneurs and companies interested in Utah’s bio […]

SINTX’s advanced ceramic manufacturing platform supports customers across multiple industries requiring high-performance materials.

Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk

The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.

AI-powered voice analysis is now available to clinicians directly inside Zoom, transforming routine telehealth conversations into early signals for behavioral and cognitive health

The Utah Pavilion will serve as a gathering place to help convention attendees discover the state’s vibrant life sciences industry and the sector’s unique culture of collaboration that drives innovation.

The designation follows encouraging Phase 2 clinical trial results.

Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.

Visit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer.

First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs.

The study, published in the Journal of Arthroplasty, highlighted that the Company’s NeuroCuple® Nanotechnology Device achieved statistically significant reduction in opioid use.

Build It Live at the HITLAB World Cup.

The DSMB review was conducted as part of the pre-planned clinical safety oversight process agreed upon with the U.S. FDA.